< Back to previous page
Researcher
Chris Marine
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
Affiliations
- Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Marine Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Member
From1 Oct 2013 → Today - Department of Human Genetics (Department)
Member
From1 Oct 2009 → 31 Dec 2016
Projects
41 - 50 of 62
- The NEAT1-paraspeckles pathway as a potential target for RNA-based cancer therapeutics.From1 Sep 2014 → 31 Dec 2018Funding: IWT personal funding - strategic basic research grants
- A Tale of NEAT1 TailsFrom15 Jul 2014 → 1 Sep 2020Funding: Nonprofit institution or equivalents
- Microfluidics for single-cell omics. the C1 Single-Cell Auto Prep System, BioMark HD System and IFC controllers (Fluidigm) for single-cell analysesFrom19 May 2014 → 18 Nov 2018Funding: Hercules - Small and Medium size research infrastructure
- Restoration of p53 function for antimelanoma combination therapy.From1 Jan 2014 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
- Determining the mode of tumor growth in melanoma by lineage tracing.From1 Jan 2014 → 31 Dec 2017Funding: FWO research project (including WEAVE projects)
- Establishment of an in vivo platform of patient-derived xenografts of several tumor types to study tailored cancer treatment.From1 Oct 2013 → 30 Sep 2018Funding: BOF - Concerted Research Project from 1994
- Determining the mode of tumor growth in melanoma by lineage tracing.From1 Oct 2013 → 30 Sep 2016Funding: FWO fellowships
- Exploring the contribution of “phenotype switching” in melanoma progression, invasion and metastatic dissemination in a refined mouse model of melanoma.From1 Aug 2013 → 3 Jun 2019Funding: FWO fellowships
- An oncogenomics-based in vivo screen to identify melanoma progression and metastasis driversFrom30 Nov 2012 → 27 Jun 2017Funding: Own budget, for example: patrimony, inscription fees, gifts
- Targeting MDM4 abundance as a promising avenue for cancer therapyFrom1 Oct 2012 → 3 Nov 2016Funding: Nonprofit institution or equivalents
Publications
1 - 10 of 158
- Cell States in Cancer: Drivers, Passengers, and Trailers.(2024)
Authors: Chris Marine
Pages: 610 - 614 - A tailored mouse model for dissecting the earliest phases of melanoma dissemination(2024)
Authors: Nina Van Raemdonck, Chris Marine
- Cancer Evolution: A Multifaceted Affair.(2024)
Authors: Chris Marine
Pages: 36 - 48 - A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma(2024)
Authors: Dennis Pedri, Ewout Landeloos, Yannick Van Herck, Katy Vandereyken, Thierry Voet, Wim Annaert, Diether Lambrechts, Veerle Boecxstaens, Joost van den Oord, Francesca Bosisio, et al.
- Deciphering melanoma transcriptional heterogeneity: TCF4 and the mesenchymal-like switch(2023)
Authors: Dennis Pedri, Wim Annaert, Chris Marine
- Tumor endothelial cell autophagy is a key vascular-immune checkpoint in melanoma(2023)
Authors: Francesca Rizzollo, Johan Van Weyenbergh, Oliver Bechter, Francesca Bosisio, Chris Marine, Diether Lambrechts, Gabriele Bergers, Patrizia Agostinis
- STmut: a framework for visualizing somatic alterations in spatial transcriptomics data of cancer(2023)
Authors: Chris Marine
- Perivascular niches: critical hubs in cancer evolution(2023)
Authors: Ada Nowosad, Chris Marine, Panagiotis Karras
Pages: 897 - 910 - Development of novel methods for single-cell whole-genome amplification to study cancer heterogeneity.(2023)
Authors: Koen Theunis, Thierry Voet, Chris Marine
- The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells (vol 21, pg 525, 2007)(2023)
Authors: Chris Marine
Pages: 861 - 861
Patents
1 - 10 of 10
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Direct and selective inhibition of mdm4 for treatment of cancer (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Inhibition of a lncrna for treatment of melanoma (Inventor)